Key Takeaways
- • Audax Private Equity portfolio company Belmont Medical Technologies acquired Arcos, a clinical software developer specializing in burn and trauma resuscitation guidance, marking Belmont's third add-on acquisition since Audax's December 2017 platform investment.
- • Arcos's flagship products—Burn Navigator (launched 2013) and BloodNav (launched 2022)—provide real-time clinical decision support for burn resuscitations and massive transfusion protocols, with BloodNav designed to integrate directly with Belmont's Rapid Infuser IV platform.
- • The acquisition expands Belmont's strategic positioning from hardware-only provider to integrated critical-care solution combining fluid management equipment, temperature control systems, and clinical decision-support software in a single workflow ecosystem.
- • Belmont Medical, founded in 1980 and headquartered in Billerica, Massachusetts, operates under CEO Brian Larkin and markets the Rapid Infuser RI-2 as its core product for high-volume warmed fluid delivery during trauma and surgical interventions.
- • Audax, managing approximately $19.5 billion in assets, continues sector consolidation within middle-market medical technology, having completed over 1,400 add-on acquisitions across its portfolio of more than 180 platform companies.
Summary
Audax Private Equity has advanced its consolidation strategy in critical-care medical technology through Belmont Medical Technologies' acquisition of Arcos, a Houston-area software developer focused on clinical decision-support systems for burn and trauma resuscitation. The transaction represents Belmont's third add-on acquisition under Audax ownership since the private equity firm acquired the platform in December 2017, following earlier purchases of HC LIFE Ltd. (United Kingdom) and MTRE Advanced Technologies' temperature management product lines in 2018.
Belmont Medical, established in 1980 and based in Billerica, Massachusetts, manufactures critical-care equipment including the Rapid Infuser RI-2, which delivers warmed blood and fluids using electromagnetic induction heating technology, alongside portable warming systems (Buddy Lite) and temperature management platforms (Allon and CritiCool). The company operates under CEO Brian Larkin and has evolved from a specialized rapid-infusion manufacturer into a broader critical-care solutions provider through its acquisition strategy.
Arcos, founded in 2009 by Dr. George Kramer and led by CEO Chris Meador, develops software platforms that guide clinicians through complex resuscitation protocols. Burn Navigator, launched in 2013, provides real-time fluid administration guidance for adult and pediatric burn patients using patient-specific clinical data; the platform has supported thousands of burn cases across U.S. and international treatment centers. BloodNav, introduced in 2022, tracks blood products, calculates transfusion ratios, delivers protocol alerts, and integrates with electronic medical record systems. Critically, BloodNav mounts directly on Belmont's Rapid Infuser IV pole, creating a hardware-software integration that links equipment, data, and clinical workflow without adding physical space constraints in trauma bays.
The acquisition reflects broader industry consolidation in medical technology toward integrated solutions pairing hardware with software and service offerings. For hospital trauma and emergency departments already operating Belmont equipment, the combination delivers a comprehensive platform addressing fluid delivery, temperature management, and real-time clinical decision-making across burn, trauma, and massive transfusion protocols. According to Meador, the integration aims to improve patient care through streamlined massive transfusion protocol performance and blood-product documentation.
Audax, headquartered in Boston with offices in San Francisco, New York, London, and Hong Kong, manages approximately $19.5 billion in assets through its $5.25 billion seventh fund. The firm targets middle-market companies with $20–$80 million EBITDA and has invested in more than 180 platform companies while completing over 1,400 add-on acquisitions across its portfolio.
Belmont Medical, established in 1980 and based in Billerica, Massachusetts, manufactures critical-care equipment including the Rapid Infuser RI-2, which delivers warmed blood and fluids using electromagnetic induction heating technology, alongside portable warming systems (Buddy Lite) and temperature management platforms (Allon and CritiCool). The company operates under CEO Brian Larkin and has evolved from a specialized rapid-infusion manufacturer into a broader critical-care solutions provider through its acquisition strategy.
Arcos, founded in 2009 by Dr. George Kramer and led by CEO Chris Meador, develops software platforms that guide clinicians through complex resuscitation protocols. Burn Navigator, launched in 2013, provides real-time fluid administration guidance for adult and pediatric burn patients using patient-specific clinical data; the platform has supported thousands of burn cases across U.S. and international treatment centers. BloodNav, introduced in 2022, tracks blood products, calculates transfusion ratios, delivers protocol alerts, and integrates with electronic medical record systems. Critically, BloodNav mounts directly on Belmont's Rapid Infuser IV pole, creating a hardware-software integration that links equipment, data, and clinical workflow without adding physical space constraints in trauma bays.
The acquisition reflects broader industry consolidation in medical technology toward integrated solutions pairing hardware with software and service offerings. For hospital trauma and emergency departments already operating Belmont equipment, the combination delivers a comprehensive platform addressing fluid delivery, temperature management, and real-time clinical decision-making across burn, trauma, and massive transfusion protocols. According to Meador, the integration aims to improve patient care through streamlined massive transfusion protocol performance and blood-product documentation.
Audax, headquartered in Boston with offices in San Francisco, New York, London, and Hong Kong, manages approximately $19.5 billion in assets through its $5.25 billion seventh fund. The firm targets middle-market companies with $20–$80 million EBITDA and has invested in more than 180 platform companies while completing over 1,400 add-on acquisitions across its portfolio.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.